the hiv investment case -- uganda · 2020-02-03 · achieving global targets 0 10,000 20,000 30,000...

15
SENSITIVE BUT UNCLASSIFIED The HIV Investment Case -- Uganda Presented by Karusa Kiragu, UNAIDS Country Director, Uganda and John Stover, Avenir Health, USA Tuesday January 28, 2020

Upload: others

Post on 28-Jul-2020

0 views

Category:

Documents


0 download

TRANSCRIPT

Page 1: The HIV Investment Case -- Uganda · 2020-02-03 · Achieving global targets 0 10,000 20,000 30,000 40,000 50,000 60,000 70,000 80,000 90,000 2010 2015 2020 2025 2030 New HIV Infections

SENSITIVE BUT UNCLASSIFIED

The HIV Investment Case -- Uganda

Presented by

Karusa Kiragu, UNAIDS Country Director, Uganda

and

John Stover, Avenir Health, USA

Tuesday January 28, 2020

Page 2: The HIV Investment Case -- Uganda · 2020-02-03 · Achieving global targets 0 10,000 20,000 30,000 40,000 50,000 60,000 70,000 80,000 90,000 2010 2015 2020 2025 2030 New HIV Infections

SENSITIVE BUT UNCLASSIFIED

What is an HIV Investment Case?

• The HIV Investment Case is a value proposition which describes how the Uganda government, working together with its partners and stakeholders, will help to improve the HIV response over the next 10 years.

• It describes how a stronger, more efficient and results-oriented government will serve the people of Uganda to achieve established targets.

• It makes the argument why the solutions Uganda proposes, will be able to solve the problem based on:• Understanding the HIV situation• ‘Designing efficient programs• Delivering at scale and• Sustaining for impact with adequate funding.

Page 3: The HIV Investment Case -- Uganda · 2020-02-03 · Achieving global targets 0 10,000 20,000 30,000 40,000 50,000 60,000 70,000 80,000 90,000 2010 2015 2020 2025 2030 New HIV Infections

SENSITIVE BUT UNCLASSIFIED

How is it being done?

• Leadership: Uganda AIDS Commission and the AIDS Control Program

• Advisors: Technical working group comprised of several thematic areas (HIV Prevention; Care and Treatment; Social Support; Systems Strengthening); guided by a steering committee

• Expertise: Will be prepared by the same team that did the last HIV Investment Case for Uganda

• Consultations: Participatory consultations with stakeholders

• Process: Modelling various intervention scenarios and projecting HIV outcomes to find the most optimal for the investment

Page 4: The HIV Investment Case -- Uganda · 2020-02-03 · Achieving global targets 0 10,000 20,000 30,000 40,000 50,000 60,000 70,000 80,000 90,000 2010 2015 2020 2025 2030 New HIV Infections

SENSITIVE BUT UNCLASSIFIED

What will be the product?

The final product is a document which explains:

1. What are the results of the current investments?

2. How much should Uganda spend in the future and what will Uganda get?

3. What needs to be improved?

4. Where will the money come from?

Page 5: The HIV Investment Case -- Uganda · 2020-02-03 · Achieving global targets 0 10,000 20,000 30,000 40,000 50,000 60,000 70,000 80,000 90,000 2010 2015 2020 2025 2030 New HIV Infections

SENSITIVE BUT UNCLASSIFIED

How will it be used?

1. To inform the HIV National Strategic Plan

2. To inform the Global Fund application

3. To support other financing dialogues

Page 6: The HIV Investment Case -- Uganda · 2020-02-03 · Achieving global targets 0 10,000 20,000 30,000 40,000 50,000 60,000 70,000 80,000 90,000 2010 2015 2020 2025 2030 New HIV Infections

SENSITIVE BUT UNCLASSIFIED

Modeling to Support the Development of the NSP and

the Investment Case28 January 2020

Page 7: The HIV Investment Case -- Uganda · 2020-02-03 · Achieving global targets 0 10,000 20,000 30,000 40,000 50,000 60,000 70,000 80,000 90,000 2010 2015 2020 2025 2030 New HIV Infections

SENSITIVE BUT UNCLASSIFIED

National HIV and AIDS Strategic Plan 2015/16 – 2019/20

Zero new HIV infections, zero HIV-related mortality, zero stigma

Prevention Care and treatmentSocial support and

protectionSystems

strengthening

Page 8: The HIV Investment Case -- Uganda · 2020-02-03 · Achieving global targets 0 10,000 20,000 30,000 40,000 50,000 60,000 70,000 80,000 90,000 2010 2015 2020 2025 2030 New HIV Infections

SENSITIVE BUT UNCLASSIFIED

Modeling for the NSP

Inputs• Pop data• Surveys• Program data• Unit costs

Targets• Prevention• Tx cascade• Social enablers• Efficiencies

Model calculations• Need for services• Behaviors• Transmission• Progression• Mortality

Services provided • Intervention• Population group

Outputs• New infections• AIDS deaths• Cost• Cost-

effectiveness

Page 9: The HIV Investment Case -- Uganda · 2020-02-03 · Achieving global targets 0 10,000 20,000 30,000 40,000 50,000 60,000 70,000 80,000 90,000 2010 2015 2020 2025 2030 New HIV Infections

SENSITIVE BUT UNCLASSIFIED

Constant Coverage

0

10,000

20,000

30,000

40,000

50,000

60,000

70,000

80,000

90,000

2010 2015 2020 2025 2030

New HIV Infections

Constant

0

10,000

20,000

30,000

40,000

50,000

60,000

70,000

80,000

90,000

2010 2015 2020 2025 2030

AIDS-Related Deaths

Constant

Page 10: The HIV Investment Case -- Uganda · 2020-02-03 · Achieving global targets 0 10,000 20,000 30,000 40,000 50,000 60,000 70,000 80,000 90,000 2010 2015 2020 2025 2030 New HIV Infections

SENSITIVE BUT UNCLASSIFIED

Achieving global targets

0

10,000

20,000

30,000

40,000

50,000

60,000

70,000

80,000

90,000

2010 2015 2020 2025 2030

New HIV Infections

Constant Targets

0

10,000

20,000

30,000

40,000

50,000

60,000

70,000

80,000

90,000

2010 2015 2020 2025 2030

AIDS-Related Deaths

Constant Targets

Target scenario achieves UNAIDS updated Fast-Track targets. Stars represent 75%/90% reduction from 2010 to 2020/2030.

Page 11: The HIV Investment Case -- Uganda · 2020-02-03 · Achieving global targets 0 10,000 20,000 30,000 40,000 50,000 60,000 70,000 80,000 90,000 2010 2015 2020 2025 2030 New HIV Infections

SENSITIVE BUT UNCLASSIFIED

Epidemic transition: Targets achieved

0.0

0.2

0.4

0.6

0.8

1.0

1.2

1.4

1.6

1.8

2010 2012 2014 2016 2018 2020 2022 2024 2026 2028 2030

Incidence – Mortality Ratio

Ratio Target

0

0.01

0.02

0.03

0.04

0.05

0.06

0.07

0.08

0.09

2010 2012 2014 2016 2018 2020 2022 2024 2026 2028 2030

Incidence – Prevalence Ratio

Ratio Target

Page 12: The HIV Investment Case -- Uganda · 2020-02-03 · Achieving global targets 0 10,000 20,000 30,000 40,000 50,000 60,000 70,000 80,000 90,000 2010 2015 2020 2025 2030 New HIV Infections

SENSITIVE BUT UNCLASSIFIED

Importance of addressing social enablers

0

10,000

20,000

30,000

40,000

50,000

60,000

70,000

80,000

90,000

2010 2015 2020 2025 2030

New HIV Infections

Constant Targets No Social Enablers

0

10,000

20,000

30,000

40,000

50,000

60,000

70,000

80,000

90,000

2010 2015 2020 2025 2030

AIDS-Related Deaths

Constant Targets No Social Enablers

Social enablers: Programs to address stigma, gender-based violence, decriminalization, human rights

Page 13: The HIV Investment Case -- Uganda · 2020-02-03 · Achieving global targets 0 10,000 20,000 30,000 40,000 50,000 60,000 70,000 80,000 90,000 2010 2015 2020 2025 2030 New HIV Infections

SENSITIVE BUT UNCLASSIFIED

Resources Needed

$0

$200

$400

$600

$800

$1,000

$1,200

$1,400

2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030

Mill

ion

s

Base Targets

Funding gap

Page 14: The HIV Investment Case -- Uganda · 2020-02-03 · Achieving global targets 0 10,000 20,000 30,000 40,000 50,000 60,000 70,000 80,000 90,000 2010 2015 2020 2025 2030 New HIV Infections

SENSITIVE BUT UNCLASSIFIED

Closing the funding gap: optimizing allocation and improving implementation efficiency

0

5,000

10,000

15,000

20,000

25,000

30,000

35,000

40,000

45,000

2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030

New HIV Infections

Optimized = Current spending optimized for maximum preventionImplementation efficiencies = Optimized plus implementation changes to reduce costs

Constant coverage

Constant expenditures (optimized)Implementation efficiencies

Targets achieved

Page 15: The HIV Investment Case -- Uganda · 2020-02-03 · Achieving global targets 0 10,000 20,000 30,000 40,000 50,000 60,000 70,000 80,000 90,000 2010 2015 2020 2025 2030 New HIV Infections

SENSITIVE BUT UNCLASSIFIED

NSP Components

Prevention• Condoms• VMMC• PMTCT• PrEP• PEP• Combination

prevention for key populations

• Combination prevention for AGYW

• Services for priority populations

Treatment• HIV testing services• Linkage to care• ART delivery• Adherence support

Social enablers• Reduce stigma • Prevent gender-based

violence• Decriminalize behaviors

Social protection and support• Human rights• OVC

System strengthening• Governance• Financial sustainability• Human resources• Service delivery• Research